Medicines Co. sees Q2 income gains on strong Angiomax sales
The Medicines Company has announced an increase in its financial outcome for the second quarter of 2010, which ended June 30.

Net income was $15.4 million, compared with net income of $3.8 million for the second quarter 2009, according to the Parsippany, N.J.-based company. Its total net revenue increased to $110.1 million for the second quarter from $104.2 million for the second quarter 2009.

For its U.S. bivalirudin (Angiomax) sales, The Medicines Company said sales increased to $104.4 million compared with $98.8 million for the second quarter 2009. However, its international sales also increased—Angiomax/Angiox international net revenue increased to $5.8 million compared with $4.5 million for the second quarter 2009.